RxDoctor Payments Data

Shawn Field, MD

Family Medicine · Hazlet, NJNPI 1417913021

Payments from drug & device makers

$5,938in general payments, 2019–2025

Across 146 payments — averaging $40.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Abbott$1K
  • AstraZeneca$707
  • Amgen$705
  • Takeda Pharmaceuticals U.S.A., Inc.$420
  • GSK$336
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$5,90599%
  • Education$331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,938 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$237,889
Medicare patients
354
Services billed
2,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol113$133,397
OzempicSemaglutide95$128,676
MounjaroTirzepatide83$123,053
JardianceEmpagliflozin106$94,976
EliquisApixaban81$90,729
TrulicityDulaglutide34$59,650
JanuviaSitagliptin Phosphate31$42,252
ProliaDenosumab23$40,124
KerendiaFinerenone37$39,422
RybelsusSemaglutide27$38,932
XareltoRivaroxaban26$28,298
EntrestoSacubitril/Valsartan14$24,590
TrintellixVortioxetine Hydrobromide23$19,661
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$19,133
JanumetSitagliptin Phos/Metformin Hcl25$17,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$190$182,703117 claims
Novo NordiskOzempic, Rybelsus$17$167,608122 claims
AstraZenecaFarxiga$707$133,397113 claims
Boehringer IngelheimJardiance$200$94,976106 claims
MerckJanuvia, Janumet, Janumet Xr$22$73,68179 claims
AmgenProlia$705$40,12423 claims
BayerKerendia$115$39,42237 claims
GSKTrelegy Ellipta, Breo Ellipta$336$31,05838 claims
Johnson & JohnsonXarelto$13$28,29826 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$420$19,66123 claims
AbbVieSynthroid$1,581$4,13674 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Hazlet

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →